News & Updates
Filter by Specialty:
Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023
byAudrey Abella
In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.
Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023Meal replacement-based diet beneficial to T2D patients
22 Nov 2023
A dietary pattern based on meal replacement (MR), compared with conventional diabetic diets (CDs), brings about improvements in glycaemic control and adipose indicators in patients with type 2 diabetes (T2D), according to a study.
Meal replacement-based diet beneficial to T2D patients
22 Nov 2023Healthy lifestyle helps prevent CHD despite genetic susceptibility to obesity
19 Nov 2023
People with high or medium genetic risk of abdominal obesity but who have a healthy lifestyle are less likely to develop coronary heart disease (CHD) than those with low genetic risk and an unhealthy lifestyle, a study has shown.